Brana, I., Berger, R., Golan, T., Haluska, P., Edenfield, J., Fiorica, J., . . . Gray, J. E. (2014). A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer.
シカゴスタイル引用形Brana, I., et al. "A Parallel-arm Phase I Trial of the Humanised Anti-IGF-1R Antibody Dalotuzumab in Combination With the AKT Inhibitor MK-2206, the MTOR Inhibitor Ridaforolimus, or the NOTCH Inhibitor MK-0752, in Patients With Advanced Solid Tumours." Br J Cancer 2014.
MLA引用形式Brana, I., et al. "A Parallel-arm Phase I Trial of the Humanised Anti-IGF-1R Antibody Dalotuzumab in Combination With the AKT Inhibitor MK-2206, the MTOR Inhibitor Ridaforolimus, or the NOTCH Inhibitor MK-0752, in Patients With Advanced Solid Tumours." Br J Cancer 2014.